Monday, October 6

(The presenters of gray titles did not allow the online appearance of their lectures )

1. MOLECULAR AND CELLULAR BIOLOGY OF CANCER

ROOM A, 08.00-12.00 – Monday, October 6

Chair Persons: S. Smith, M.R.J. Kohonen-Corish

Senescence linked inflammation, replication stress, fragile sites and DNA methylation changes in sporadic breast and prostate cancer. S. Smith (Duarte, CA, USA) (20’)
Identification of a new molecular pathway for beta-catenin regulation in colon cancer cells. L. Pangon, D. N. Mladenova, N. Currey, P. Lecine, J.P. Borg, M.R.J. Kohonen-Corish (Sydney, Australia; Marseille, France) (15’)
Stimulation of fatty acid synthesis by thyroid hormone response protein/spot14 enhances tumor cell proliferation in vivo. E.A. Wellberg, M.C. Rudolph, A. Lewis, S.M. Anderson (Aurora, CO, USA) (30’)
Tryptophan metabolism, neopterin and cancer. J.M. Gostner, K. Becker, F. Ueberall, D. Fuchs (Innsbruck, Austria) (30’)
Roles for vickz proteins in cell migration, cancer progression, and metastasis. Y. Maizels, Y.B.-Z. Rosenfeld, F. Oberman, Z. Fridlender, J. K. Yisraeli (Jerusalem, Israel) (30’)
Role of acetylcholine as a growth factor: focus on urinary bladder. N. Arrighi, D. Zani, M.C. Michel, S. Sigala (Brescia, Italy; Mainz, Germany) (30’)
Protein folding and cancer. J. Anastassopoulou, M. Kyriakidou, S. Kyriazis, V. Dritsa, T. Kormas ( Athens, Greece) (20’)
In-silico identification of novel bacterial antigenic proteins as potential vaccine targets against gastric cancer using reverse vaccinology approaches. A. Naz, F.M. Awan, A. Obaid, A. Ali (Islamabad, Pakistan) (15’)
Target PI3K/AKT-related lipid kinase pathways for treatment of advanced cancer. J. Persson (Malmö, Sweden) (30′)

2. ONCOGENES; TUMOR SUPPRESSOR GENES; GROWTH FACTORS; SIGNAL TRANSDUCTION

ROOM A, 13.00-16.15 – Monday, October 6

Chair Persons: D.W. Felsher, A. Seth

Modeling and predicting consequences of therapeutic oncogene inactivation. D.W. Felsher (Stanford, CA, USA) (40’)
Activating BRAF and PIK3CA mutations cooperate to promote anaplastic thyroid carcinogenesis. R.P. Charles, J. Silva, G. Iezza, W.A. Phillips, M. McMahon (San Francisco, CA, USA; Melbourne, Australia; Bern, Switzerland) (30’)
Post-translational regulation of COX2 activity by FYN in prostate cancer cells. A. Sorokin (Milwaukee, WI, USA) (25’)
Tumor suppressor protein IGFBP7 blocks phosphatidylinositol-3-kinase-AKT signaling by binding to the IGF-1 receptor. Y. Amemiya, T. Benatar, V. Evdokimova, W. Yang, A. Seth (Toronto,ON, Canada) (15’)
Steroid receptor co-activators and oestrogen receptor beta-1 isoform as survival biomarkers in malignant pleural mesothelioma. C.J. Jennings, B. Murer, A. O’Grady, B.J. Harvey, E.W. Kay, W. Thomas (Dublin, Ireland; Mestre, Italy) (30’)
From bench to bed, from single gene to multiplex analysis, and challenges and accomplishments in fighting lung cancer. S. Long, G. Otterson, D. Carbone, M. Villalona, Y.Tang, K. Shilo, W. Zhao (Columbus, OH, USA) (15’)
Right-sided tumours and related unexplained iron-deficiency anaemia(IDA) are associated with BRAF V600E mutation in colorectal cancer patients. M. Sideris, K. Adams, J. Moorhead, S. Diaz-Cano, S. Papagrigoriadis (London, UK) (10’)

3. EPIGENETICS

ROOM A, 16.30-19.00 – Monday, October 6

Chair Persons: W. Engström, G. Broich

Mitotic bookmarking of genes- a novel dimension of epigenetic memory in cancer. S.Sengupta, L. Bellot, S. Nath, K.K. Bhakat (Omaha, NE USA) (40’)
Epigenetic regulation of the igf2/h19 locus. W. Engström, M. Nordin, D. Bergman, M. Halje, C. Laestander, E. Andersson, M.A. Lindgren, I. Lindstedt (Uppsala, Sweden) (30’)
Epigenetic and DNA-conformation mediated regulation of gene expression in breast cancer. A. Ray, B.K. Ray (Columbia, MO, USA) (30’)
Epigenetic regulations and the Vitamin D system. E. Kallay (Vienna, Austria) (20’)

4. NEW ANTICANCER AGENTS

ROOM B, 08.00-10.00 – Monday, October 6

Chair Persons: L. Amaral, S. Shany

Family of peptides synthesized in the human body have anticancer effects. D.L. Vesely (Tampa, FL, USA) (40′)
Cancer therapy with radionuclides from the natural radioactive series. R.H. Larsen, Ø.S. Bruland (Oslo, Norway) (30′)
Mechanism-based sirtuin inhibition. W. Zheng (Zhenjiang, Jiangsu, PR China) (40′)

5. NEW ANTICANCER AGENTS

ROOM B, 10.00-12.00 Monday, October 6

Chair Persons: H. Maeda, D.L. Vesely

TCP-1 as a novel phage-display peptide targeting colon cancer. C.H. Cho, L. Lu (Shatin, Hong Kong) (20′)
Inhibition of vitamin D degradation enhances its activity against human lung cancer cell growth. S. Shany, V. Gavrilov (Beer Sheva, Israel) (30′)
L-asparaginases as therapeutic enzymes for the treatment of leukemia. C.S. Karamitros, M. Konrad (Goettingen, Germany) (20′)
Gossypol analogs and Bcl-2 protein – Natural compounds and natural target. V. Gandhi (Houston, TX, USA) (20′)
Cytotoxic effect of gentisic acid and protocatechuic acid triphenylphosphonium derivatives in human breast cancer cells: Possible mechanism and bioenergetic implications. C. Sandoval-Acuña, S. Fuentes-Retamal, D. Guzman-Rivera, H. Speisky, V. Castro-Castillo, M. Madrid-Rojas, J. Ferreira (Santiago, Chile) (10′)

6. DRUG DELIVERY
Special Symposium Organized by D. Vetvicka

ROOM B, 13.00-17.30 – Monday, October 6

Chair Person: D. Vetvicka

Nanomedicine for cancer selective drug delivery; Advantages of the EPR effect and pitfalls. H. Maeda, H. Nakamura, J. Fang (Kumamoto, Japan) (30′)
Polymer-drug conjugates for targeted tumor therapy. T. Etrych, P. Chytil, E. Koziolová, M. Šírová, S. Hoffman, T. Müller, K. Mäder, B. Ríhová, K. Ulbrich (Prague, Czech Republic) (30′)
Bionanotechnology and novel targeted drug delivery systems. A. Syed (Edinburgh, UK) (30′)
Ultrasound-responsive systems for targeted cancer therapy. A.P. McHale, K. Curtis, N. Nomikou, B. Callan, J.F. Callan (Coleraine, Northern Ireland; London, UK) (30′)
Experimental topical photodynamic therapy of cancer with liposomal hydroxy-aluminium phthalocyanine. D. Vetvicka, M. Zadinova, M. Nekvasil, P. Jezek, J. Rakusan, M. Karaskova, J. Kralova, V. Kral, P. Pouckova (Prague; Rybitvi, Czech Republic) (30′)
Tumor regression after intravenous administration of novel tumour-targeted nanomedicines. C. Dufès (Glasgow, UK) (30′)
The Atomic Force Microscopy (AFM) in nanomedicine. D.A. Lamprou (Glasgow, Scotland, UK) (30′)
Polymer donors of nitric oxide for enhanced accumulation of anticancer agent in the solid tumor microenvironment. M. Studenovský, M. Šírová, B. Ríhová, K. Ulbrich (Prague, Czech Republic) (15′)

7. EXPERIMENTAL CHEMOTHERAPY

ROOM B, 17.45-19.30 – Monday, October 6

Chair Persons: L. Helson, S. Palakurthi, V. Treska

Oral formulation of a liposome breakdown product mitigates intravenous Moxifloxacin induced QTc prolongation in vivo. L. Helson, G. Shopp, A. Bouchard, M. Majeed, D. Salvail, W. Shaw (Boulder, CO,; Winsdor, NJ, USA; Sherbrooke, QC, Canada) (30′)
Nano polymer-cisplatin complexes for chemotherapy of ovarian cancer. S. Palakurthi, V.K. Yellepeddi (Kingsville, TX, USA) (30′)
The promise of sonodynamic therapy: using ultrasonic irradiation and chemotherapeutic agents as a treatment modality. M. Trendowski (Syracuse, NY, USA) (15′)
Portal vein embolisation with the application of haematopoietic stem cells in patients with primarily non-resectable colorectal liver metastases. V. Treska, V. Liska, J. Fichtl, D. Lysak, H. Mirka, J. Bruha, P. Duras (Pilsen, Czech Republic) (15′)

8. DIAGNOSIS AND PROGNOSIS OF CANCER

ROOM C, 08.00-09.50 – Monday, October 6

Chair Persons: S. Arbak, T. Dalianis, T. Theophanides

Human papillomavirus (HPV) and other biomarkers for prediction of clinical outcome in oropharyngeal squamous cell carcinoma (OPSCC). A. Näsman, C. Nordfors, N. Tertipis, N. Grün, J. Du, A. Ährlund-Richter, L. Haeggblom, L. Sivars, A. Vlastos, D. Lindquist, L. Hammarstedt Nordvall,L.Marklund, E. Munck-Wikland, T. Ramqvist, T. Dalianis (Stockholm; Umea, Sweden) (15’)
Infrared spectroscopy applied to cancer studies.T. Theophanides, J. Anastassopoulou (Athens Greece) (20’)
Proline-rich tyrosine kinase 2 and its phosphorylated form pY881 are novel prognostic markers for non-small cell lung cancer progression and patients’ overall survival. B.-H. Kuang, M.-Q. Zhang, L.-H. Xu, L.-J. Hu, H.-B. Wang, W.-F. Zhao, Y. Du, X. Zhang (Guangzhou; Zhengzhou, China, PR) (15’)
Altered epigenetic signature of circulating cell-free nucleosomes in colon and prostate cancer. M. Herzog, M. Chapelier, G. Cuvelier, K. Scoubeau, E. Josseaux, D. Pamart, M. Eccleston, J. Micallef (Namur, Belgium)(15’)
Diagnostic approach and prognostic factors in colorectal cancer. I.D. Tzeveleki (Thessaloniki, Greece) (15’)
Prediction of the fast tumoricide effect of transarterial application of 90-yttrium glass-microspheres, a potential role of dual-energy ct (review). J. Ferda, P. Duras, V. Treška, T. Skalický, J. Fínek, O. Topolcan (Pilsen, Czech Republic) (15’)

9. CLINICAL CHEMOTHERAPY

ROOM C, 10.00-12.00 – Monday, October 6

Chair Persons: F. Muggia, R. Klapdor

Endometrial cancer: Building the systemic therapy backbone. F. Muggia (New York, NY, USA) (40’)
16 years experience with an efficacy orientated sequential polychemotherapy of exocrine pancreatic cancer. R. Klapdor (Hamburg, Germany) (15’)
A clinical phase I study on administration of high dose sodium selenite as a treatment of cancer – the SECAR study. O. Brodin, M. Wallenberg, S. Misra, M. Björnstedt (Stockholm, Sweden) (25’)
Combinations of platinums and phytochemicals administered to ovarian tumour models. S. Althurwi, J.Q. Yu, P. Beale, C. Chan, F. Huq (Sydney, NSW, Australia) (10’)
Mistakes in prostatic carcinoma assessment on multiparametric 3t mri: non-pirads and pirads evaluation versus whole-mount section histology. J. Ferda, J. Kastner, E. Ferdová, J. Baxa, R. Fuchsová, M. Hora, O. Hes, O. Topolcan (Pilsen, Czech Republic) (15’)

10. IMMUNOTHERAPY; BIOTHERAPY; VACCINES

ROOM C, 13.00-15.30 – Monday, October 6

Chair Persons: Y. Keisari, S. Kumar

Induction of anti-metastatic immune response by alpha radiation or electrochemical tumour ablation. Y. Keisari, H. Confino, I. Hochman , M. Efrati, M. Schmidt, V. Umansky, I. Kelson, R. Korenstein (Tel Aviv, Israel; Heidelberg; Mannheim, Germany) (30’)
Deconstructing inflammatory signaling pathway that promotes drug resistance and metastatic competence in cancer cells. K. Mehta (Houston, TX, USA) (30’)
Use of oncolytic viral vaccines to treat cancer. B.D. Lichty, Y. Wan, D.F. Stojdl, J.C. Bell, J.G. Pol, K.B. Stephenson, M.J. Atherton, B.W. Bridle (Hamilton; Ottawa; Guelph, ON, Canada) (30’)
The importance of the immunomodulatory protein, the progesterone induced blocking factor, in allowing cancer cells to escape immune surveillance and therapeutic considerations. J.H. Check (Camden, NJ, USA) (30’)

11. IMMUNOTHERAPY; BIOTHERAPY; VACCINES

ROOM C, 15.45-18.00 – Monday, October 6

Chair Persons: D. Characiejus, F. Guadagni

12. TARGETING THE TUMOUR MICROENVIRONMENT (A)
Special Symposium Organized by I.P. Witz and Y. Keisari

ROOM D, 8.00-12.00 – Monday, October 6

Chair Persons: I.P. Witz, Y. Keisari

Metastasis and the metastatic microenvironment. I. P. Witz (Tel Aviv, Israel) (40’)
The mechanism of tumor cell trafficking. D. Naor (Jerusalem, Israel) (30’)
Mechanisms underlying the pro-tumorigenic effect of CXCL14-expressing cancer-associated fibroblasts. M. Augsten, E. Sjöberg,O. Frings, J. Frijhoff and A. Östman (Stockholm, Sweden) (30’)
Immunosuppression in melanoma microenvironment induced by chronic inflammation. V. Umansky, A. Sevko, J. Utikal (Heidelberg, Baden-Württemberg, Germany) (30’)
Do cancer cells impose epigenetic changes on normal fibroblasts? A colon-oriented preliminary inquiry. S. Lamprecht, J. Delinasios, A. Fich, N. Abu Freha (Beer-sheva, Israel; Kapandriti, Greece) (20’)
Galectin-1 in crosstalk between cancer cells and cancer-associated fibroblasts. K. Smetana Jr, B. Dvoránková , R. Mateu , J. Kucera , A. Mifková , Z. Fík , J.-M. Lehn , H.-J. Gabius (Prague, Czech Republic; Strasbourg, France; Munich, Germany) (30’)
The role of micro-RNAs in steroid induced apoptosis of hemopoietic cancers. S. Kfir, N.Haggiag, E. Yefenof (Jerusalem, Israel) (30’)

13. TARGETING THE TUMOUR MICROENVIRONMENT (B)
Special Symposium Organized by D. D. Spyropoulos and G. Sica

ROOM D, 13.00-17.00 – Monday, October 6

Chair Persons: D. D. Spyropoulos, G. Sica

Enzymatic remodeling of the tumor microenvironment enhances substantial changes in malignant cell phenotype and increased efficacy in combination with chemotherapy. H. M. Shepard , C. Thompson and J. Huang (San Diego, CA, USA) (30’)
Metabolic reprogramming during stromal aging and cancer progression. J. Son, E.H. Sarsour, J. Fussell, J. Lafin, A.L. Kalen, P.C. Goswami (Iowa City, IA, USA) (30’)
Tissue Banking and 3D ‘ex vivo‘ models for personalized medicine. J.E. Baatz, D.A. Newton, E.C. Riemer, C.E. Denlinger, E.E. Jones, R.R. Drake and D.D. Spyropoulos (Charleston, SC, USA) (30’)
Breast cancer-associated fibroblasts promote tumor cell migration: crucial role of stearoyl-CoA desaturase 1 and paracrine signalings. C. Angelucci, G. Maulucci, A. Colabianchi, F. Iacopino, A. D’Alessio, A. Maiorana, V. Palmieri, M. Papi, M. De Spirito, A. Di Leone, R. Masetti, G. Sica (Rome, Italy) (30’)
Cell type – specific gene expression analysis at the infiltrative margins of glioma. A. Dovas, B. Gill, D. Pisapia, H. Malone, H. Goldstein, L. Lei, A. Sonabend, J. Yun, J. Samanamud, J. Sims, M. Banu, A.F. Teich, S. Sheth, G. McKhann, M. Sisti, J.N Bruce, P. Sims and P. Canoll (New York, NY, USA) (15’)
Immuno-modulatory properties of cancer-associated fibroblasts. L. Gorch, T. Hellevik, T.B. Stuge, I. Martinez-Zubiaurre (Tromso, Norway) (15’)
Tumor microenvironment of metastasis in head and neck cancer. S. Koontongkaew (Prathum thani, Thailand) (20’)
Cell-cell interactions between transformed and non-transformed epithelial cells: the role of e-cadherin. N.A. Gloushankova, S.N. Rubtsova, I.Y. Zhitnyak (Moscow, Russia) (20’)

14. CIRCULATING TUMOR CELLS
Special Symposium Organized by M.Rigaud

ROOM D, 17.15-19.35 – Monday, October 6

Chair Persons: M. Rigaud, S.S. Martin

Targeting microtentacles on circulating breast tumor cells to reduce metastasis. A.E. Boggs, M.S. Charpentier, M.I. Vitolo, R.A. Whipple, K. Thomson, L. Bhandary, K. Chakrabarti, O.B. Ioffe, Y. Lu, G.B. Mills and S.S. Martin (Baltimore, MD, USA) (30’)
High throughput few and single cell expression profiling and the characterization of circulating tumor cells. M. Kubista, R. Sjöback, M. Jindrichova, E. Rohlova, V. Rusnakova, S. Hauch, B. Aktas, M. Tewes, M. Bredemeier, S. Kasimir-Bauer (Langenhagen; Essen, Germany) (30’)
EML4-ALK investigation in mNSCLC patient CTCs using an in vivo procedure. G. Gallerani, M. Zoli, P. Fici, S. Bravaccini, M. Tumedei, A. Delmonte, M.A. Burgio,C. Casadei, F. Fabbri (Bologna; Ferrara; Meldola, Italy) (15’)
EMT ratio as CTC aggressiveness index. P. Fici, G. Gallerani, M. Rigaud, F. Fabbri (Meldola; Bologna, Italy) (15’)
A new medical device for in vivo isolation of circulating tumor cells – clinical validation and overview of potential target. S. Herold, L. Gasiorowski, P. Nowaczyk, A. Schumann, G.Theil, J. Tucholski, B. Nowack, T. Krahn, W. Dyszkiewicz, D. Murawa, K. Lücke (Potsdam, Germany) (25’)
A microfluidic CTC sorting strategy using self-assembled magnetic particles. E. Tulukguoglu, C. Bureau, K. Perez-Toralla, S. Descroix, L. Malaquin, J.Y. Pierga, F.C. Bidard, J.L. Viovy (Paris; Fluigent; France) (15′)

15. CARCINOGENESIS; VIRAL ONCOGENESIS

ROOM E, 08.00-09.30 – Monday, October 6

Chair Persons: W. Engström, A.R. Young

Photoprotection by sunscreens and skin cancer. A.R. Young (London, UK) (30’)
The HALIFAX project – an attempt to assess the carcinogenicpotential of low dose exposures to chemical mixtures in the environment. W. Engström, T. Hultman, L. Lowe (Uppsala, Sweden; Nova Scotia, Canada) (15’)
A metal exposured cohort study in the largest metal workers population in the world. Y. Bai (Lanzhou, Gansu, PR China) (15’)

16. ALTERNATIVE AND COMPLEMENTARY MEDICINE IN CANCER TREATMENT
Special Symposium Organized by S. Pathak

ROOM E, 9.40-12.00 – Monday, October 6

Chair Persons: B.B. Aggarwal, S. Pathak

17. MULTI-DRUG AND DRUG RESISTANCE: MECHANISMS AND REVERSAL

ROOM E, 13.00-16.00 – Monday, October 6

Chair Persons: T. Efferth, J. Molnar

Inhibition of P-glycoprotein in cancer cells by synthetic and natural compounds. T. Efferth, M. Zeino, M. Volm (Mainz; Heidelberg, Germany) (40’)
Targeting BAG-1-mediated protein interactions to overcome BRAF inhibitor resistance. M. Enthammer, M. Thurner, S. Khalid, H. Stuppner H, R.I. Cutress, J. Troppmair (Innsbruck, Austria; Southampton, UK) (30’)
“Quadrugnostic” nanoparticles for overcoming anticancer drug resistance and for diagnostics. R. Edelmana, Y.G. Assarafb, R. Goldschmidta, I. Levitzkia, T. Shahara, A. Slavkina, Y. D. Livney (Haifa, Israel) (30’)
Cisplatin-associated protein contributes to cisplatin resistance and malignancy in thyroid carcinoma. A. Derwiysh, R. Arsenic, H. Lage (Berlin, Germany) (15‘)
Induction of activating transcription factor 3 is associated with cisplatin responsiveness in NSCLC. J. Bar, D. Stewart, G.D. Goss, J. Villeneuve, J. Dimitroulakos (Ottawa, Ontario, Canada) (15’)

18. THE SUGAR CODE IN TUMOR BIOLOGY/PATHOLOGY: PRINCIPLES AND EXAMPLES
Special Symposium Organized by H.J. Gabius

ROOM E, 16.00-19.00 – Monday, October 6

Chair Persons: H.J. Gabius, K. Kayser, J. Kopitz, K. Smetana Jr

Introduction to the sugar code in tumor biology/pathology: Principles and examples. H.J. Gabius, K. Kayser, J. Kopitz, K. Smetana Jr (Munich; Berlin; Heidelberg, Germany; Prague, Czech Republic) (30’)
A primer to the function of glycoproteins and glycolipids in tumor biology. J. Kopitz (Heidelberg, Germany) (30’)
How human lectins translate the sugar code. H.J. Gabius (Munich, Germany) (30’)
Galectins in squamous cell carcinomas. K. Smetana Jr (Prague, Czech Republic; Munich, Germany) (30’)
Structural entropy and lectins: partners in analyzing biological information at the cellular level. K. Kayser (Berlin, Germany) (30’)

19. CANCER GENOMICS. MICROARRAY TECHNOLOGY

ROOM F, 8.00-10.00 – Monday, October 6

Chair Persons: D. Anderson, D.-T. Bau

Demystifying the dark matter of the human proteome: Implications for novel biomarkers and drug targets. R. Narayanan (Boca Raton, FL, USA) (30’)
Quantitative proteomic profiling of fromalin-fixed paraffin-embedded (FFPE) prostate cancer tissues. D. Iglesias-Gato (Copenhagen, Denmark) (20’)
Translational network for predictive, preventive, personalized and participatory cancer study. D-T Bau, C-W Tsai, W-S Chang, C-M Hsu (Taichung, Taiwan, ROC) (30’)
Profiling of chromosomal changes in potentially malignant and malignant oral mucosal lesions from South and South-East Asia using Array – Comparative genomic hybridization. M.S. Lunde, E. Roman, S. Warnakulasuriya, R. Mehrotra, J. Laranne, E.N. Vasstrand and S.O. Ibrahim (Bergen, Norway; London, UK; Allahabad, India; Tampere, Finland) (15’)

20. CANCER GENOMICS. MICROARRAY TECHNOLOGY

ROOM F, 10.00-12.30 – Monday, October 6

Chair Persons: R. Narayanan, C. Nicolini

Sensitivity and specificity of the empirical lymphocyte genome sensitivity (LGS) Assay: Implications for improving cancer diagnostics. D. Anderson, M. Najafzadeh, R. Gopalan, N. Ghaderi, A. J. Scally, S.T. Britland, B.K. Jacobs, P.D. Reynolds, J. Davies, A. L. Wright, S. Al-Ghazal, D. Sharpe, M.C. Denyer (Bradford, West Yorkshire, UK) (30’)
Clinical cancer proteomics: models for personalized medicine. A.A. Alaiya (Riyadh, Saudi Arabia) (30’)
Determination of protein-protein interaction for cancer control via mass spectrometry and conductimetry of nappa-snap microrrays. C. Nicolini, E. Pechkova (Bergamo, Italy) (30’)
LB based nanocrystallography at the frontiers of cancer proteomics. E. Pechkova, C. Nicolini (Genova, Italy) (20’)
The study of genomic contribution in Taiwan head and neck cancers. C.-W. Tsai, C.-M. Hsu, W.-S. Chang, D.-T. Bau (Taichung,Taiwan) (15’)

21. GENOMIC INSTABILITY AND CANCER (DNA REPAIR)
Special Symposium Organized by A.A. Wani

ROOM F, 13.00-19.30 – Monday, October 6

Chair Persons: A.A. Wani, R.M. Snapka

Chromatin structure and ionizing radiation signaling. T.K. Pandita (Houston, TX, USA) (40’)
Ubiquitination and deubiquitination of DNA repair factors : Modulation by modification. J. He, Q. Zhu, G. Wani, N. Sharma, C. Han, J. Qian, K. Pentz, Q. Wang and A.A. Wani (Columbus, OH,USA) (30’)
DNA damage-induced regulation of base excision repair protein stability and ARTD1 activation. R.W. Sobol (Pittsburg, PA, USA) (30’)
Regulatory mechanisms of transcription-coupled DNA repair. S. Malik, P. Chaurasia, R. Sen, S. Lahudkar, G. Durairaj, B. Uprety, S. R. Bhaumik (Carbondale, IL, USA) (40’)
Single stranded DNA binding protein 1 recruits TERT to telomeres. R.K. Pandita, D. Udayakumar, C.R. Hunt, N. Horikoshi, T.K. Pandita (Houston, TX, USA) (40’)
Thymoquinone inhibition of autophagy causes growth inhibition and caspase-independent death of glioblastoma cells. R.M. Snapka, I.O. Racoma, W.H. Meisen, Q.-E. Wang, B. Kaur, A.A. Wani (Ohio,USA) (30’)
ROS mechanisms mediate the inhibition of oral cancer by avocado extract. H. Ding, B. Casto, Y. Deng, K. Grill, W. Duan, N. Zhang, S. Cole, K. La Perle, X. Pan, A.D. Kinghom, S.M. D’Ambrosio (Columbus , OH, USA) (25’)
DNA damage responses in ovarian cancer stem cells. A. K. Srivastava, C. Han, R. Zhao, T. Cui, Q.-E. Wang (Columbus , OH, USA) (30’)
Oxidative genome damage repair deficiency in a human DNA glycosylase NEIL2 variant: Potential linkage to lung cancer susceptibility. T. Hazra (Galveston, TX, USA) (30’)